A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

Exclusion Criteria

• •Known type 1 diabetes, or positive GAD65 or IA2 antibodies, or history of diabetic ketoacidosis or hyperglycemic hyperosmolar syndrome.
• •A history of, or at risk for pancreatitis.
• •Self or family history of Multiple Endocrine Neoplasia (MEN) type 2A or B, thyroid C-cell hyperplasia or medullary thyroid cancer, or a blood calcitonin result ≥20 picograms per milliliter (pg/ml) at screening.
• •A systolic blood pressure of ≥160 millimeters of mercury (mmHg) or diastolic ≥100 mmHg.
• •Active or treated cancer.
• •A blood disorder where an accurate HbA1c may not be obtainable.
• •A female of childbearing age, sexually active and not on birth control.
• •Pregnant or plan to be pregnant during the study, or breastfeeding.
• •Taking any diabetic medication other than metformin or basal insulin and have not stopped it 3 months prior to the screening visit (6 weeks for bolus or mealtime insulin).
• •Have taken oral steroids within the last 60 days or more than 20 days use within the past year or 1000 micrograms fluticasone propionate per day.
• •Using prescription weight loss medications in the last 30 days, or plan to use.
• •Taking psychiatric medications for depression or illness or attention deficit hyperactivity disorder (ADHD) if, the doses has changed within the last 3 months.